Acknowledgments
We thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K. Warren, Jr. Chair in
Medicine (to C.W.L.).
References
1.
2.
3.
4.
Feliciangeli S, Chatelain FC, Bichet D, Lesage F. The family of K2P channels: salient structural and functional properties. J Physiol.
2015;593(12):2587–2603.
Medhurst AD, Rennie G, Chapman CG, Meadows H, Duckworth MD, Kelsell RE, Gloger II, Pangalos MN. Distribution analysis of human two pore
domain potassium channels in tissues of the central nervous system and periphery. Brain Res Mol Brain Res. 2001;86(1-2):101–114.
Devilliers M, Busserolles J, Lolignier S, Deval E, Pereira V, Alloui A, Christin M, Mazet B, Delmas P, Noel J, Lazdunski M, Eschalier A. Activation
of TREK-1 by morphine results in analgesia without adverse side effects. Nat Commun. 2013;4:2941.
Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM,
Debonnel G, Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci.
2006;9(9):1134–1141.
5.
Royal P, Andres-Bilbe A, Ávalos Prado P, Verkest C, Wdziekonski B, Schaub S, Baron A, Lesage F, Gasull X, Levitz J, Sandoz G. Migraine-
Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK. Neuron.
2019;101(2):232–245.e6.
6.
7.
Tong L, Cai M, Huang Y, Zhang H, Su B, Li Z, Dong H. Activation of K(2)P channel-TREK1 mediates the neuroprotection induced by sevoflurane
preconditioning. Br J Anaesth. 2014;113(1):157–167.
Lugenbiel P, Wenz F, Syren P, Geschwill P, Govorov K, Seyler C, Frank D, Schweizer PA, Franke J, Weis T, Bruehl C, Schmack B, Ruhparwar A,
Karck M, Frey N, Katus HA, Thomas D. TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and
provide therapeutic targets for rhythm control. Basic Res Cardiol. 2017;112(1):8.
8.
9.
Loucif AJC, Saintot PP, Liu J, Antonio BM, Zellmer SG, Yoger K, Veale EL, Wilbrey A, Omoto K, Cao L, Gutteridge A, Castle NA, Stevens EB,
Mathie A. GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P) channel opener, reduces rat dorsal root ganglion
neuron excitability. Br J Pharmacol. 2018;175(12):2272–2283.
(a) Danthi S, Enyeart JA, Enyeart JJ. Caffeic acid esters activate TREK-1 potassium channels and inhibit depolarization-dependent secretion. Mol
Pharmacol. 2004;65(3):599–610. (b) Rodrigues N, Bennis K, Vivier D, Pereira V, C Chatelain F, Chapuy E, Deokar H, Busserolles J, Lesage F,
Eschalier A, Ducki S. Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-
1 channel. Eur J Med Chem. 2014;75:391–402.
10. Vivier D, Soussia IB, Rodrigues N, Lolignier S, Devilliers M, Chatelain FC, Prival L, Chapuy E, Bourdier G, Bennis K, Lesage F, Eschalier A,
Busserolles J, Ducki S. Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+ Channel 1-Selective Agonist Possessing in
Vivo Antinociceptive Activity. J Med Chem. 2017;60(3):1076–1088.
11. Bagriantsev SN, Ang KH, Gallardo-Godoy A, Clark KA, Arkin MR, Renslo AR, Minor DL Jr. A high-throughput functional screen identifies small
molecule regulators of temperature- and mechano-sensitive K2P channels. ACS Chem Biol. 2013;8(8):1841–1851.
12. Minieri L, Pivonkova H, Caprini M, Harantova L, Anderova M, Ferroni S. The inhibitor of volume-regulated anion channels DCPIB activates TREK
potassium channels in cultured astrocytes. Br J Pharmacol. 2013;168(5):1240–1254.
13. Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, Myers RA, Lodge NJ. BL-1249 [(5,6,7,8-
tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol
Exp Ther. 2005;313(1):250–259.
14. Juey PF, Hudyma TW, Brown M. Preparation and antiinflammatory properties of some 5-(2-anilinophenyl)tetrazoles. J Med Chem. 1968;11:111–117.
15. Pope L, Arrigoni C, Lou H, Bryant C, Gallardo-Godoy A, Renslo AR, Minor DL Jr. Protein and Chemical Determinants of BL-1249 Action and
Selectivity for K2P Channels. ACS Chem Neurosci. 2018;9:3153–3165.
16. Monteillier A, Loucif A, Omoto K, Stevens EB, Lainez S, Saintot PP, Cao L, Pryde DC. Investigation of the structure activity relationship of
flufenamic acid derivatives at the human TRESK channel K2P18.1. Bioorg Med Chem Lett, 2016:26:4919–4924.
17. Monteillier A, Loucif A, Omoto K, Stevens EB, Lainez S, Saintot PP, Cao L, Pryde DC. Investigation of the structure activity relationship of
flufenamic acid derivatives at the human TRESK channel K2P18.1. Bioorg Med Chem Lett, 2016:26:4919–4924.
18. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives
bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996;39:5228–5235.
19. Birch AM, Kenny PW, Simpson I, Whittamore PRO. Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.
Bioorg Med Chem Lett, 2009:19:850–853.
20. Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, III, Huryn DM,
Ballatore C. Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem. 2016;59(7):3183–3203.
21. Lindsley CW, Wieting JM, McGowan KD, Denton JS, Yashiro K, Kurata H, Sekioka Y, Mori T, Iwaki Y. Activator of TREK (TWIK related K+
channels) channels. WO2018110669.
Highlights
First detailed SAR account around TREK1/2 activators
First optimization campaign directed at BL-1249
Discovery of new in vitro and in vivo tool compound, ONO-2960632/VU6011992